Table 2.
Selected articles and their relevant characteristics: year of publication, study design, country, year of data, perspective, and principal study aim
| Article | Year of publication | Design | Country | Year of data | Perspective | Principal aim |
|---|---|---|---|---|---|---|
| Foo J et al. [6] | 2016 | Cross-sectional study | England | 2012–2013 | Society | To assess the economic impact of COPD based on an international survey of COPD patients. |
| Wacker M. E et al. [7] | 2016 | Cohort study | Germany | 2010–2013 | Society | To investigate COPD medical overuse, work absenteeism and resulting costs within the German COSYCONET cohort. |
| Chen W et al. [8] | 2017 | Cohort study | Canada | 1996–2012 | NHS* | To examine the impact of comorbidities on excess direct medical costs in patients with COPD. |
| Tachkov K et al. [9] | 2017 | Cohort study | Bulgaria | 2014–2015 | Patient | To calculate the economic and social burden of COPD in Bulgaria generated by lost productivity due to absence from work, early retirement, reduced productivity and DALYs. |
| Wacker M. E et al. [10] | 2017 | Cohort study | Germany | 2010–2013 | Society | To analyze the association of frequent comorbidities and common symptoms with the direct and indirect annual costs of COPD patients. |
| Quang Vo T et al. [11] | 2018 | Cohort study | Vietnam | 2015–2017 | NHS | To explore the direct medical costs associated with COPD and identify the key factors of disease management costs. |
| Lakiang T et al. [12] | 2018 | Cross-sectional study | India | 2014–2015 | Society | To study the economic impact (direct and indirect costs) of COPD patients receiving treatment in a tertiary hospital in South India. |
| Lisspers K et al. [13] | 2018 | Cohort study | Sweden | 2000–2014 | Society | To assess the direct and indirect costs of COPD in Sweden in relation to time, age and stage of disease. |
| Merino M et al. [14] | 2018 | Cohort study | Spain | 2015 | Society | To estimate the socioeconomic impact of COPD in Extremadura (Spain) in 2015. |
| Patel JG et al. [15] | 2018 | Cohort study | USA | 2007–2010 | Society | To measure the impact of COPD by calculating direct and indirect incremental costs. |
| Stafyla E et al. [16] | 2018 | Cohort study | Greece | 2014–2015 | Public decision maker | To estimate the annual cost of the COPD patient during the maintenance phase and to explore relationships between cost and disease severity. |
| Zhu B et al. [17] | 2018 | Systematic review | China | Until 2015 | Society | To quantify the burden of COPD in China and to determine the risk factors for the disease. |
| Changhwan Kim M. D y col [18] | 2019 | Cohort study | Corea | From 2013 | Society | To estimate the direct and indirect costs and inform the establishment of efficient strategies to reduce the financial burden of COPD in Korea. |
| Rehman A et al. [19] | 2019 | Systematic review | USA, Asia and Europe | Until 2019 | NHS | To find the economic burden of COPD in the U.S., Europe and Asia and identify key cost drivers in the treatment of COPD patients. |
| Viinanen A et al. [20] | 2019 | Cohort study | Finland | 2004–2015 | NHS | To describe healthcare resource utilization and associated costs in COPD patients in Finland according to disease severity and blood eosinophil count. |
| Woo L et al. [21] | 2019 | Systematic review | Asia and Pacific | 2000–2018 | Society | To evaluate COPD cost studies and analyze cost comparisons between Asia-Pacific countries. |
| Iheanacho I et al. [22] | 2020 | Systematic review | Worldwide | 2006–2016 | Society | To highlight the economic burden associated with moderate-severe COPD and to investigate the key drivers of healthcare resource utilization, direct and indirect costs. |
| Rehman A et al. [23] | 2020 | Systematic review | Europe | Until 2019 | Society | To estimate the economic impact of COPD and identify key cost drivers in the treatment of COPD patients in different European countries. |
*NHS: National Health System